AQR Capital Management
CCCC icon

AQR Capital Management’s C4 Therapeutics CCCC Stock Holding History

AQR Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-383,789
Closed -$549K – 3484
2025
Q2 		$549K Buy
383,789
+243,257
+173% +$354K ﹤0.01% 2570
2025
Q1 		$225K Buy
140,532
+127,244
+958% +$380K ﹤0.01% 2830
2024
Q4 		$47.8K Sell
13,288
-25,668
-66% -$128K ﹤0.01% 2810
2024
Q3 		$222K Buy
+38,956
New +$234K ﹤0.01% 2521
2024
Q1 		– Sell
-148,610
Closed -$840K – 2426
2023
Q4 		$840K Sell
148,610
-944,489
-86% -$2.15M ﹤0.01% 1665
2023
Q3 		$2.03M Buy
1,093,099
+540,895
+98% +$1.65M ﹤0.01% 1317
2023
Q2 		$1.52M Sell
552,204
-54,261
-9% -$174K ﹤0.01% 1383
2023
Q1 		$1.9M Buy
606,465
+331,373
+120% +$1.95M ﹤0.01% 1277
2022
Q4 		$1.62M Buy
275,092
+182,924
+198% +$1.52M ﹤0.01% 1347
2022
Q3 		$808K Buy
92,168
+17,439
+23% +$181K ﹤0.01% 1596
2022
Q2 		$563K Buy
+74,729
New +$658K ﹤0.01% 1643

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management's CCCC Position: Q3 2025 in Review

AQR Capital Management sold out of C4 Therapeutics (CCCC) in Q3 2025, closing a stake of 383,789 shares — an estimated $549K sold.

AQR Capital Management first reported a position in CCCC in Q2 2022 and held it in 11 quarters. The position peaked at $2.03M in Q3 2023. 97 funds tracked by Wall St. Rank hold CCCC as of Q3 2025.

  • AQR Capital Management reported no remaining C4 Therapeutics position as of Q3 2025 after selling out during the quarter.
  • AQR Capital Management sold 383,789 C4 Therapeutics shares in Q3 2025, an estimated $549K.
  • AQR Capital Management first reported a position in C4 Therapeutics in Q2 2022 and held it in 11 quarters.
  • AQR Capital Management's C4 Therapeutics position peaked at $2.03M in Q3 2023.
  • 97 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2025.

Based on AQR Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.